TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia
Brief Summary: This randomized phase III trial is studying fludarabine, cyclophosphamide, and rituximab to see how well they work compared to fludarabine and cyclophosphamide in treating patients with B-cell chronic lymphocytic leukemia.


Options:
A: Arm Label: Coronary Stent; Type: N/A; Interventions: N/A
B: Arm Label: Fludarabine+Cyclophosphamide+Rituximab (FCR); Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Arm Label: Fludarabine+Cyclophosphamide (FC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR)
C: N/A
D: Arm Label: DSE; Type: N/A; Interventions: N/A | Arm Label: CTCA; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Chemotherapy With Fludarabine and Cyclophosphamide (FC) Alone in Patients With Previously Untreated Chronic Lymphocytic Leukaemia
Brief Summary: This randomized phase III trial is studying fludarabine, cyclophosphamide, and rituximab to see how well they work compared to fludarabine and cyclophosphamide in treating patients with B-cell chronic lymphocytic leukemia.


Options:
A: Intervention Type: DRUG; Name: HuMax-CD20; Assigned to Arm(s): N/A
B: Arm Label: Active Comparator 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ofatumumab 500mg, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Active Comparator 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ofatumumab 1000mg, Drug: Fludarabine, Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Ofatumumab 500mg; Assigned to Arm(s): Active Comparator 1 | Intervention Type: DRUG; Name: Ofatumumab 1000mg; Assigned to Arm(s): Active Comparator 2 | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Active Comparator 1, Active Comparator 2 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Active Comparator 1, Active Comparator 2
C: Arm Label: Fludarabine+Cyclophosphamide+Rituximab (FCR); Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Arm Label: Fludarabine+Cyclophosphamide (FC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide, Drug: Fludarabine Phosphate | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR) | Intervention Type: DRUG; Name: Fludarabine Phosphate; Assigned to Arm(s): Fludarabine+Cyclophosphamide (FC), Fludarabine+Cyclophosphamide+Rituximab (FCR)
D: Arm Label: ofatumumab + chlorambucil; Type: EXPERIMENTAL; Interventions: Drug: chlorambucil, tablets, Drug: ofatumumab (GSK1841157) infusion | Arm Label: chlorambucil; Type: ACTIVE_COMPARATOR; Interventions: Drug: chlorambucil, tablets | Intervention Type: DRUG; Name: chlorambucil, tablets; Assigned to Arm(s): chlorambucil, ofatumumab + chlorambucil | Intervention Type: DRUG; Name: ofatumumab (GSK1841157) infusion; Assigned to Arm(s): ofatumumab + chlorambucil

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet and Telephone Counseling for Smoking Cessation
Brief Summary: RATIONALE: Computer-assisted stop-smoking plans and telephone counseling may help people stop smoking. It is not yet known which computer-based smoking cessation program is more effective with or without telephone counseling in helping smokers quit smoking.

PURPOSE: This randomized clinical trial is studying two different computer-based smoking cessation programs to compare how well they work with or without telephone counseling in helping smokers quit smoking.


Options:
A: Intervention Type: BEHAVIORAL; Name: Self-Help Intervention Program-High Blood Pressure; Assigned to Arm(s): N/A
B: Arm Label: Basic Internet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic Internet | Arm Label: Enhanced Internet; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Internet | Arm Label: Enhanced Internet plus Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Internet + phone | Intervention Type: BEHAVIORAL; Name: Basic Internet; Assigned to Arm(s): Basic Internet | Intervention Type: BEHAVIORAL; Name: Enhanced Internet; Assigned to Arm(s): Enhanced Internet | Intervention Type: BEHAVIORAL; Name: Enhanced Internet + phone; Assigned to Arm(s): Enhanced Internet plus Phone
C: Arm Label: Life Style Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: IVR intervention | Arm Label: Life Counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: IVR control | Intervention Type: BEHAVIORAL; Name: IVR intervention; Assigned to Arm(s): Life Style Counseling | Intervention Type: BEHAVIORAL; Name: IVR control; Assigned to Arm(s): Life Counseling
D: Arm Label: Clinic Quality Improvement + Behavioral Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Clinic Quality Improvement + Behavioral Counseling | Arm Label: Clinic Quality Improvement + Attention Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Clinic Quality Improvement + Attention Control | Intervention Type: BEHAVIORAL; Name: Clinic Quality Improvement + Behavioral Counseling; Assigned to Arm(s): Clinic Quality Improvement + Behavioral Counseling | Intervention Type: BEHAVIORAL; Name: Clinic Quality Improvement + Attention Control; Assigned to Arm(s): Clinic Quality Improvement + Attention Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet and Telephone Counseling for Smoking Cessation
Brief Summary: RATIONALE: Computer-assisted stop-smoking plans and telephone counseling may help people stop smoking. It is not yet known which computer-based smoking cessation program is more effective with or without telephone counseling in helping smokers quit smoking.

PURPOSE: This randomized clinical trial is studying two different computer-based smoking cessation programs to compare how well they work with or without telephone counseling in helping smokers quit smoking.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-delivered continuing professional development | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: No intervention arm | Intervention Type: BEHAVIORAL; Name: Internet-delivered continuing professional development; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: No intervention arm; Assigned to Arm(s): 2
B: Arm Label: Crush the Crave Application; Type: EXPERIMENTAL; Interventions: Behavioral: Crush the Crave Application | Arm Label: On the Road to Quitting - Self Help; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: On the Road to Quitting - Self Help | Intervention Type: BEHAVIORAL; Name: Crush the Crave Application; Assigned to Arm(s): Crush the Crave Application | Intervention Type: BEHAVIORAL; Name: On the Road to Quitting - Self Help; Assigned to Arm(s): On the Road to Quitting - Self Help
C: Arm Label: 1-800-QUIT-NOW Telephone Hotline; Type: OTHER; Interventions: Other: 1-800-QUIT-NOW Telephone Hotline | Arm Label: Tobacco Tactics Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Tactics Web-Based Intervention | Intervention Type: BEHAVIORAL; Name: Tobacco Tactics Web-Based Intervention; Assigned to Arm(s): Tobacco Tactics Intervention | Intervention Type: OTHER; Name: 1-800-QUIT-NOW Telephone Hotline; Assigned to Arm(s): 1-800-QUIT-NOW Telephone Hotline
D: Arm Label: Basic Internet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic Internet | Arm Label: Enhanced Internet; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Internet | Arm Label: Enhanced Internet plus Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Internet + phone | Intervention Type: BEHAVIORAL; Name: Basic Internet; Assigned to Arm(s): Basic Internet | Intervention Type: BEHAVIORAL; Name: Enhanced Internet; Assigned to Arm(s): Enhanced Internet | Intervention Type: BEHAVIORAL; Name: Enhanced Internet + phone; Assigned to Arm(s): Enhanced Internet plus Phone

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Internet and Telephone Counseling for Smoking Cessation
Brief Summary: RATIONALE: Computer-assisted stop-smoking plans and telephone counseling may help people stop smoking. It is not yet known which computer-based smoking cessation program is more effective with or without telephone counseling in helping smokers quit smoking.

PURPOSE: This randomized clinical trial is studying two different computer-based smoking cessation programs to compare how well they work with or without telephone counseling in helping smokers quit smoking.


Options:
A: Arm Label: Spirometry and lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking cessation advice, Behavioral: Spirometry and smoking cessation advice | Arm Label: Lifestyle counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Smoking cessation advice; Assigned to Arm(s): Spirometry and lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Spirometry and smoking cessation advice; Assigned to Arm(s): Spirometry and lifestyle counseling
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3
C: Arm Label: Basic Internet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic Internet | Arm Label: Enhanced Internet; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Internet | Arm Label: Enhanced Internet plus Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Internet + phone | Intervention Type: BEHAVIORAL; Name: Basic Internet; Assigned to Arm(s): Basic Internet | Intervention Type: BEHAVIORAL; Name: Enhanced Internet; Assigned to Arm(s): Enhanced Internet | Intervention Type: BEHAVIORAL; Name: Enhanced Internet + phone; Assigned to Arm(s): Enhanced Internet plus Phone
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Motivational Interviewing (MI) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured Brief Advice (SBA) | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing (MI); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Structured Brief Advice (SBA); Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Tolerability of Neurostimulation in Early Stage Parkinson's Disease
Brief Summary: Bilateral subthalamic nucleus deep brain stimulation (B-STN DBS) is one of the most effective surgical treatments for PD patients suffering from levodopa-induced motor complications. The relatively low incidence of permanent adverse effects and the potential for neuroprotection and alteration of the natural course of PD suggest a highly favorable benefit-to-risk ratio of this procedure. Since neuroprotection is best applied early in the disease course when there are more surviving neurons, we believe that further investigation of this procedure is warranted. The proposed pilot study will provide the necessary data to substantiate the safety and tolerability of the procedure as well as provide data for the design of a full-scale, multicenter trial to investigate the hypothesis that B-STN DBS is a safe and effective treatment to slow the progression of PD.


Options:
A: Arm Label: ODT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimal drug therapy | Arm Label: DBS+ODT; Type: EXPERIMENTAL; Interventions: Device: B-STN DBS, Drug: Optimal drug therapy | Intervention Type: DEVICE; Name: B-STN DBS; Assigned to Arm(s): DBS+ODT | Intervention Type: DRUG; Name: Optimal drug therapy; Assigned to Arm(s): DBS+ODT, ODT
B: Arm Label: Placebo; Type: SHAM_COMPARATOR; Interventions: Other: Deep brain stimulation | Arm Label: Deep Brain Stimulation; Type: ACTIVE_COMPARATOR; Interventions: Other: Deep brain stimulation | Intervention Type: OTHER; Name: Deep brain stimulation; Assigned to Arm(s): Deep Brain Stimulation, Placebo
C: Intervention Type: DEVICE; Name: high frequency stimulation; Assigned to Arm(s): N/A
D: Arm Label: Deep Brain Stimulation; Type: ACTIVE_COMPARATOR; Interventions: Other: Deep brain stimulation | Arm Label: Placebo; Type: SHAM_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: Deep brain stimulation; Assigned to Arm(s): Deep Brain Stimulation | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Telemedical and Conventional Antihypertensive Treatment
Brief Summary: The aim of the study is to compare telemedical antihypertensive treatment based on home blood pressure monitoring and conventional antihypertensive treatment based on monitoring of blood pressure in the doctor's office.

We want to test the hypotheses that telemedical treatment is more effective in lowering blood pressure, provide better quality of life and is more cost-effective.


Options:
A: Arm Label: Telemonitoring; Type: EXPERIMENTAL; Interventions: Procedure: Telemonitoring | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Telemonitoring; Assigned to Arm(s): Telemonitoring
B: Arm Label: Home blood pressure telemonitoring; Type: EXPERIMENTAL; Interventions: Device: Telemedical blood pressure monitoring | Arm Label: Conventional blood pressure monitoring; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telemedical blood pressure monitoring; Assigned to Arm(s): Home blood pressure telemonitoring
C: Arm Label: ATSM Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ATSM Intervention | Arm Label: GMV Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: GMV Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ATSM Intervention; Assigned to Arm(s): ATSM Intervention | Intervention Type: BEHAVIORAL; Name: GMV Intervention; Assigned to Arm(s): GMV Intervention
D: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Device: telemedicine program | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: telemedicine program; Assigned to Arm(s): Telemedicine

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis
Brief Summary: This was a Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of rituximab in combination with mycophenolate mofetil (MMF) compared with placebo in combination with MMF in subjects diagnosed with International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV lupus nephritis.


Options:
A: Arm Label: FK506+MMF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Multitherapy | Intervention Type: DRUG; Name: Multitherapy; Assigned to Arm(s): FK506+MMF
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: abatacept, Drug: cyclophosphamide, Drug: azathioprine, Drug: prednisone, Drug: azathioprine placebo | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: cyclophosphamide, Drug: azathioprine, Drug: prednisone, Drug: abatacept placebo | Intervention Type: DRUG; Name: abatacept; Assigned to Arm(s): Treatment | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Control, Treatment | Intervention Type: DRUG; Name: azathioprine; Assigned to Arm(s): Control, Treatment | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): Control, Treatment | Intervention Type: DRUG; Name: abatacept placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: azathioprine placebo; Assigned to Arm(s): Treatment
C: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab, Drug: Mycophenolate mofetil, Drug: Methylprednisolone, Drug: Diphenhydramine, Drug: Acetaminophen, Drug: Prednisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Mycophenolate mofetil, Drug: Methylprednisolone, Drug: Diphenhydramine, Drug: Acetaminophen, Drug: Prednisone | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Placebo, Rituximab | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Placebo, Rituximab | Intervention Type: DRUG; Name: Diphenhydramine; Assigned to Arm(s): Placebo, Rituximab | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): Placebo, Rituximab | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Placebo, Rituximab
D: Arm Label: Cyclosporine A; Type: EXPERIMENTAL; Interventions: Drug: Cyclosporine A | Arm Label: Cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Cyclosporine A; Assigned to Arm(s): Cyclosporine A | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Cyclophosphamide

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sacral Transcutaneous Nerve Stimulation Treatment for Functional Daytime Incontinence in Children With Over Active Bladder Syndrome
Brief Summary: The purpose of this study is to perform a randomized controlled investigation of the effect of surface nerve stimulation on functional daytime incontinence in children with OAB.


Options:
A: Arm Label: Surgical; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery | Arm Label: Medical Treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Medical Treatment | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Surgical | Intervention Type: PROCEDURE; Name: Medical Treatment; Assigned to Arm(s): Medical Treatment
B: Arm Label: Placebo Children; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Urotherapy | Arm Label: Solifenacin Succinate Suspension Children; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin Succinate Suspension, Behavioral: Urotherapy | Arm Label: Placebo Adolescents; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Urotherapy | Arm Label: Solifenacin Succinate Suspension Adolescents; Type: PLACEBO_COMPARATOR; Interventions: Drug: Solifenacin Succinate Suspension, Behavioral: Urotherapy | Intervention Type: DRUG; Name: Solifenacin Succinate Suspension; Assigned to Arm(s): Solifenacin Succinate Suspension Adolescents, Solifenacin Succinate Suspension Children | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Adolescents, Placebo Children | Intervention Type: BEHAVIORAL; Name: Urotherapy; Assigned to Arm(s): Placebo Adolescents, Placebo Children, Solifenacin Succinate Suspension Adolescents, Solifenacin Succinate Suspension Children
C: Intervention Type: DEVICE; Name: Nerve stimulator; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mictonetten 5 mg, coated tablet | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mictonetten 5 mg, coated tablet; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: (Intraarterial Progenitor Cell Transplantation of Bone Marrow Mononuclear Cells for Induction of Neovascularization in Patients With Peripheral Arterial Occlusive Disease)
Brief Summary: Patients with peripheral artery disease, stage III or IV who are not candidates for interventional or operative therapy should be treated with intraarterial progenitor cell therapy (autologous bone marrow cells) in a randomized, placebo controlled trial.


Options:
A: Intervention Type: GENETIC; Name: Autologous bone marrow cells; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intraarterial stem cell therapy, Other: Stem cells | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: intraarterial stem cell therapy, Other: Stem cells | Intervention Type: PROCEDURE; Name: intraarterial stem cell therapy; Assigned to Arm(s): 1, 2 | Intervention Type: OTHER; Name: Stem cells; Assigned to Arm(s): 1, 2
C: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
D: Arm Label: MultiGeneAngio; Type: EXPERIMENTAL; Interventions: Biological: MultiGeneAngio | Intervention Type: BIOLOGICAL; Name: MultiGeneAngio; Assigned to Arm(s): MultiGeneAngio

Answer: B